Imprimis Epinephrine-Lidocaine Injections Recall: Subpotent Epinephrine Risk
Imprimis recalls epinephrine-lidocaine eye injections due to potential underactive epinephrine. Affected lots may not work properly during eye procedures. Contact FDA for adverse events.
Lower-risk recall
Subpotent: Failing Test Results for Epinephrine
Contact the company
What happened, in plain English
Imprimis NJOF recalls certain epinephrine-lidocaine eye injections because they may contain less active epinephrine than labeled. This could lead to ineffective treatment during eye procedures if used as intended. Read more at govinfonow.com/recall/33069-imprimis-epinephrine-lidocaine-injections-recall-subpotent-epinephrine-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/33069-imprimis-epinephrine-lidocaine-injections-recall-subpotent-epinephrine-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0040-2024
Cite this page
“Imprimis Epinephrine-Lidocaine Injections Recall: Subpotent Epinephrine Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33069-imprimis-epinephrine-lidocaine-injections-recall-subpotent-epinephrine-risk. Based on FDA recall #D-0040-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0040-2024%22&limit=1).
Why it’s dangerous
The injections may have lower-than-stated epinephrine levels, which could result in ineffective treatment during eye procedures. This is a subpotency issue where the product doesn't meet the required strength for its intended use.
Who’s affected
Healthcare professionals using these injections for eye procedures. Patients receiving the injections are at risk if the product fails to deliver proper medication.
How to tell if you have this one
Check for the lot number 23APR018 on the packaging. The product is a 1mL single-use intraocular injection with NDC 71384-640-01, compounded on April 24, 2023, and expires April 17, 2024.
- Brand
Imprimis NJOF- Category
Drug
What to do — step by step
Check Product Details
Look for lot number 23APR018 on the packaging to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
How do I report an adverse event?
Contact the FDA at www.fda.gov/medwatch or call (800)-FDA-1088 if you experience issues.
Contact Imprimis NJOF
We’ve drafted a message you can send Imprimis NJOF to request your refund or repair — edit it as you like.
Subject: Recall D-0040-2024 — Imprimis NJOF Imprimis Epinephrine-Lidocaine Injections Recall: Subpotent Epinephrine Risk Hello, I own a Imprimis Epinephrine-Lidocaine Injections Recall: Subpotent Epinephrine Risk that is covered by recall D-0040-2024 from Imprimis NJOF. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0040-2024 (October 3, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0040-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.